Announced merger agreement with Eos SENOLYTIX in March Closed private placement of preferred stock FRAMINGHAM, Mass., May 15, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company")...

Series B Preferred Stock investment made in Pulmatrix with a conversion price of $2.20 is a part of the ongoing merger process FRAMINGHAM, Mass., April 21, 2026 /PRNewswire/ -- Pulmatrix, Inc....

Combined company to operate as Eos SENOLYTIX, a first-in-class anti-aging biotechnology company $19 million financings to advance lead clinical candidate PTC-2105 for sarcopenia and age-related...

Cullgen had been seeking approval for a merger with Pulmatrix from the China Securities Regulatory Commission and on February 28, 2026, notified Pulmatrix that Cullgen was terminating the Merger...

Plans to License or Monetize our Migraine and Inhalation Assets Continue FRAMINGHAM, Mass., Feb. 26, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a...

Pulmatrix continues to support Cullgen in seeking approval for their merger from the China Securities Regulatory Commission FRAMINGHAM, Mass., Dec. 18, 2025 /PRNewswire/ -- Pulmatrix, Inc....

As part of the proposed merger, Pulmatrix currently intends to divest its assets including its proprietary dry powder delivery technology, iSPERSE™, which enables delivery of small- or...

Proposed merger anticipated to close in 2025 As part of the proposed merger, Pulmatrix currently intends to divest its assets including its proprietary dry powder delivery technology, iSPERSE™,...

Registration statement for proposed Cullgen merger declared effective by the SEC Proposed merger anticipated to close in June As part of proposed merger, Pulmatrix currently intends to divest its...

Announced merger agreement with Cullgen in November, anticipated to close in the first half of 2025 As part of proposed merger, Pulmatrix intends to divest its assets including its Phase 2-ready...